Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LA JOLLA PHARMACEUTICAL COLJPC · Entity 124310 | Chief Medical Officer | July 01, 2020 | September 17, 2020 |
| REVELATION BIOSCIENCES, INC.REVB · Entity 8359 | Director | August 17, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LA JOLLA PHARMACEUTICAL CO
Report date July 01, 2020 · Filed September 17, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,447 |
Reported balance
After 2020-09-15 transaction · row 1
1 source rowRow 1 · 2020-09-15 · Grant · Acquired 286 · Balance 13,447 F1: These shares were acquired on 09/15/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.53 · Expires 2030-09-15 | Direct | 286 |
Reported balance
After 2020-09-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-09-15 · Grant · Acquired 286 · Balance 286 F2: The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vest and become exercisable ratably on a monthly basis over the next three years. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.52 · Expires 2030-07-01 | Direct | 60,000 |
Reported balance
After 2020-07-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-07-01 · Grant · Acquired 60,000 · Balance 60,000 F2: The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vest and become exercisable ratably on a monthly basis over the next three years. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired on 09/15/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2: The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vest and become exercisable ratably on a monthly basis over the next three years.
REVELATION BIOSCIENCES, INC.
Report date August 17, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,169 |
Reported balance
After 2026-08-17 transaction · row 1
1 source rowRow 1 · 2026-08-17 · Grant · Acquired 32,011 · Balance 44,169 F1: These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 31, 2019 Filed Nov 5, 2019 16:05 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 96 | $5.96 | $572.16 |
DisclosureSEC source: 0000920465-19-000151 · wf-form4_157298790491069.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,594 F1 · kind: These shares were acquired on 10/31/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 17:41 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 81 | $0.00 Strike: $8.38 | $0.00 |
DisclosureSEC source: 0000920465-19-000144 · wf-form4_157134848046426.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81 Underlying: Common Stock · 81 shares Expires 2029-10-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 17:41 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 81 | $7.12 | $576.72 |
DisclosureSEC source: 0000920465-19-000144 · wf-form4_157134848046426.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,498 F1 · kind: These shares were acquired on 10/15/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 17:05 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 76 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0000920465-19-000135 · wf-form4_157005026880224.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76 Underlying: Common Stock · 76 shares Expires 2029-09-30 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 17:05 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 76 | $7.48 | $568.48 |
DisclosureSEC source: 0000920465-19-000135 · wf-form4_157005026880224.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,417 F1 · kind: These shares were acquired on 09/30/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| September 13, 2019 Filed Sep 16, 2019 19:23 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 62 | $0.00 Strike: $10.92 | $0.00 |
DisclosureSEC source: 0000920465-19-000126 · wf-form4_156867621251886.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62 Underlying: Common Stock · 62 shares Expires 2029-09-13 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| September 13, 2019 Filed Sep 16, 2019 19:23 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 62 | $9.28 | $575.36 |
DisclosureSEC source: 0000920465-19-000126 · wf-form4_156867621251886.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,341 F1 · kind: These shares were acquired on 09/13/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| August 30, 2019 Filed Sep 3, 2019 16:12 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 70 | $0.00 Strike: $9.57 | $0.00 |
DisclosureSEC source: 0000920465-19-000119 · wf-form4_156754152569994.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70 Underlying: Common Stock · 70 shares Expires 2029-08-30 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| August 30, 2019 Filed Sep 3, 2019 16:12 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 70 | $8.13 | $569.10 |
DisclosureSEC source: 0000920465-19-000119 · wf-form4_156754152569994.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,279 F1 · kind: These shares were acquired on 08/30/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 16:51 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 72 | $0.00 Strike: $9.43 | $0.00 |
DisclosureSEC source: 0000920465-19-000111 · wf-form4_156598864497643.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72 Underlying: Common Stock · 72 shares Expires 2029-08-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 16:51 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 72 | $8.02 | $577.44 |
DisclosureSEC source: 0000920465-19-000111 · wf-form4_156598864497643.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,209 F1 · kind: These shares were acquired on 08/15/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 16:59 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 80 | $0.00 Strike: $8.36 | $0.00 |
DisclosureSEC source: 0000920465-19-000104 · wf-form4_156477956480487.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80 Underlying: Common Stock · 80 shares Expires 2029-07-31 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 16:59 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 80 | $7.11 | $568.80 |
DisclosureSEC source: 0000920465-19-000104 · wf-form4_156477956480487.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,137 F1 · kind: These shares were acquired on 07/31/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 17:10 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 73 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0000920465-19-000095 · wf-form4_156339779185616.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73 Underlying: Common Stock · 73 shares Expires 2029-07-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 17:10 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 73 | $7.85 | $573.05 |
DisclosureSEC source: 0000920465-19-000095 · wf-form4_156339779185616.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,057 F1 · kind: These shares were acquired on 07/15/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 28, 2019 Filed Jul 1, 2019 18:11 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 73 | $0.00 Strike: $9.25 | $0.00 |
DisclosureSEC source: 0000920465-19-000091 · wf-form4_156201905670778.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73 Underlying: Common Stock · 73 shares Expires 2029-06-28 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| June 28, 2019 Filed Jul 1, 2019 18:11 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 73 | $7.86 | $573.78 |
DisclosureSEC source: 0000920465-19-000091 · wf-form4_156201905670778.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,984 F1 · kind: These shares were acquired on 06/28/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 14, 2019 Filed Jun 18, 2019 16:44 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 69 | $0.00 Strike: $9.71 | $0.00 |
DisclosureSEC source: 0000920465-19-000087 · wf-form4_156089063638333.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69 Underlying: Common Stock · 69 shares Expires 2029-06-14 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| June 14, 2019 Filed Jun 18, 2019 16:44 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 69 | $8.25 | $569.25 |
DisclosureSEC source: 0000920465-19-000087 · wf-form4_156089063638333.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,911 F1 · kind: These shares were acquired on 06/14/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 19:27 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 126 | $0.00 Strike: $5.39 | $0.00 |
DisclosureSEC source: 0000920465-19-000086 · wf-form4_155960446132665.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126 Underlying: Common Stock · 126 shares Expires 2029-05-31 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 19:27 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 126 | $4.58 | $577.08 |
DisclosureSEC source: 0000920465-19-000086 · wf-form4_155960446132665.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,842 F1 · kind: These shares were acquired on 05/31/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| May 15, 2019 Filed May 17, 2019 16:06 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 102 | $0.00 Strike: $6.57 | $0.00 |
DisclosureSEC source: 0000920465-19-000080 · wf-form4_155812358546077.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102 Underlying: Common Stock · 102 shares Expires 2029-05-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| May 15, 2019 Filed May 17, 2019 16:06 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 102 | $5.58 | $569.16 |
DisclosureSEC source: 0000920465-19-000080 · wf-form4_155812358546077.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,716 F1 · kind: These shares were acquired on 05/15/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 30, 2019 Filed May 2, 2019 17:11 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 84 | $0.00 Strike: $8.05 | $0.00 |
DisclosureSEC source: 0000920465-19-000069 · wf-form4_155683144562859.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84 Underlying: Common Stock · 84 shares Expires 2029-04-30 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| April 30, 2019 Filed May 2, 2019 17:11 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 84 | $6.84 | $574.56 |
DisclosureSEC source: 0000920465-19-000069 · wf-form4_155683144562859.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,614 F1 · kind: These shares were acquired on 04/30/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 17:05 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 94 | $0.00 Strike: $7.16 | $0.00 |
DisclosureSEC source: 0000920465-19-000064 · wf-form4_155553512809278.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94 Underlying: Common Stock · 94 shares Expires 2029-04-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 17:05 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 94 | $6.09 | $572.46 |
DisclosureSEC source: 0000920465-19-000064 · wf-form4_155553512809278.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,530 F1 · kind: These shares were acquired on 04/15/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 19:06 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 35 | $0.00 Strike: $6.43 | $0.00 |
DisclosureSEC source: 0000920465-19-000056 · wf-form4_155424635314737.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35 Underlying: Common Stock · 35 shares Expires 2029-03-29 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 19:06 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 35 | $5.47 | $191.45 |
DisclosureSEC source: 0000920465-19-000056 · wf-form4_155424635314737.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,436 F1 · kind: These shares were acquired on 03/29/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 17:06 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 29 | $0.00 Strike: $7.64 | $0.00 |
DisclosureSEC source: 0000920465-19-000053 · wf-form4_155302863776881.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29 Underlying: Common Stock · 29 shares Expires 2029-03-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 17:06 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 29 | $6.49 | $188.21 |
DisclosureSEC source: 0000920465-19-000053 · wf-form4_155302863776881.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,401 F1 · kind: These shares were acquired on 3/15/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 17:31 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 40 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0000920465-19-000046 · wf-form4_155173867769357.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40 Underlying: Common Stock · 40 shares Expires 2029-02-28 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 17:31 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 40 | $4.85 | $194.00 |
DisclosureSEC source: 0000920465-19-000046 · wf-form4_155173867769357.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,372 F1 · kind: These shares were acquired on 02/28/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 18:12 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 36 | $0.00 Strike: $6.23 | $0.00 |
DisclosureSEC source: 0000920465-19-000037 · wf-form4_155061793721092.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36 Underlying: Common Stock · 36 shares Expires 2029-02-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 18:12 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 36 | $5.30 | $190.80 |
DisclosureSEC source: 0000920465-19-000037 · wf-form4_155061793721092.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,332 F1 · kind: These shares were acquired on 02/15/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 18:12 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 37 | $0.00 Strike: $6.04 | $0.00 |
DisclosureSEC source: 0000920465-19-000026 · wf-form4_154932191007225.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37 Underlying: Common Stock · 37 shares Expires 2029-01-31 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 18:12 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 37 | $5.13 | $189.81 |
DisclosureSEC source: 0000920465-19-000026 · wf-form4_154932191007225.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,296 F1 · kind: These shares were acquired on 01/31/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 30, 2019 Filed Jan 31, 2019 18:49 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 200 | $5.57 | $1,114.00 |
DisclosureSEC source: 0000920465-19-000025 · wf-form4_154897857940267.xml · nonDerivative · entry 4 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,259 Read SEC document |
| January 30, 2019 Filed Jan 31, 2019 18:49 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 800 | $5.57 | $4,455.92 |
DisclosureSEC source: 0000920465-19-000025 · wf-form4_154897857940267.xml · nonDerivative · entry 3 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,059 Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 18:49 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 1,200 | $5.57 | $6,684.00 |
DisclosureSEC source: 0000920465-19-000025 · wf-form4_154897857940267.xml · nonDerivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,259 Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 18:49 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 800 | $5.55 | $4,440.00 |
DisclosureSEC source: 0000920465-19-000025 · wf-form4_154897857940267.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,059 Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 22:00 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 53,000 | $0.00 Strike: $5.99 | $0.00 |
DisclosureSEC source: 0000920465-19-000023 · wf-form4_154847158944549.xml · derivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,000 Underlying: Common Stock · 53,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 20:53 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 72 | $0.00 Strike: $6.75 | $0.00 |
DisclosureSEC source: 0000920465-19-000014 · wf-form4_154777639587877.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72 Underlying: Common Stock · 72 shares Expires 2029-01-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 20:53 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 72 | $5.74 | $413.28 |
DisclosureSEC source: 0000920465-19-000014 · wf-form4_154777639587877.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,259 F1 · kind: These shares were acquired on 01/15/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 19:53 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 23 | $0.00 Strike: $9.43 | $0.00 |
DisclosureSEC source: 0000920465-19-000005 · wf-form4_154656320625002.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23 Underlying: Common Stock · 23 shares Expires 2028-12-31 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 19:53 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 23 | $8.02 | $184.36 |
DisclosureSEC source: 0000920465-19-000005 · wf-form4_154656320625002.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,187 F1 · kind: These shares were acquired on 12/31/2018 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 14, 2018 Filed Dec 17, 2018 20:30 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 17 | $0.00 Strike: $12.80 | $0.00 |
DisclosureSEC source: 0000920465-18-000069 · wf-form4_154509659821819.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17 Underlying: Common Stock · 17 shares Expires 2028-12-14 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| December 14, 2018 Filed Dec 17, 2018 20:30 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 17 | $10.88 | $184.96 |
DisclosureSEC source: 0000920465-18-000069 · wf-form4_154509659821819.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,164 F1 · kind: These shares were acquired on 12/14/2018 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 21:56 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 16 | $0.00 Strike: $14.47 | $0.00 |
DisclosureSEC source: 0000920465-18-000061 · wf-form4_154389214836443.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16 Underlying: Common Stock · 16 shares Expires 2028-11-30 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 21:56 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 16 | $12.30 | $196.79 |
DisclosureSEC source: 0000920465-18-000061 · wf-form4_154389214836443.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,147 F1 · kind: These shares were acquired on 11/30/2018 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.